The FDA must finalize its review by October 15 to determine if satralizumab-mwge (Enspryng)—currently approved for neuromyelitis optica spectrum disorder—can also treat thyroid eye disease (TED). The agency in June granted Genentech’s supplemental biologics license application (sBLA) Priority Review status.
Should the FDA give the green light, satralizumab would represent a novel therapeutic approach for thyroid eye disease (TED) by inhibiting the interleukin-6 (IL-6) receptor instead of the insulin-like growth factor-1 receptor (IGF-1R), which is targeted by existing treatments like teprotumumab (Tepezza) and veligrotug-vvze (veligrotug/Lumvoa).
Satralizumab Mechanism and Clinical Trials
Although IL-6 inhibition isn’t completely new in TED management, another drug that blocks the IL-6 receptor, tocilizumab (Actemra), has already been prescribed off-label, especially for individuals with corticosteroid-resistant, active disease. The regulatory submission draws strength from two phase 3 SatraGO trials.
In the SatraGO program, satralizumab achieved its main goal in SatraGO-2 but missed the mark in SatraGO-1; nonetheless, secondary outcomes related to inflammation and double vision leaned in favor of the therapy across both studies. As a humanized monoclonal antibody, satralizumab suppresses signaling via the IL-6 receptor—an immune pathway tied to the autoimmune mechanisms behind TED.
This drug has been FDA-approved since 2020 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody-positive. For NMOSD, the approved regimen consists of 120 mg subcutaneously at weeks 0, 2, and 4, followed by 120 mg every 4 weeks.
Thyroid Eye Disease Explained
Thyroid eye disease is a rare autoimmune condition affecting the eyes that can result in proptosis, double vision, eye irritation, and in worse cases, threats to sight. Before newer treatments emerged, doctors mainly relied on oral or intravenous steroids to reduce swelling, while surgeries addressed lingering symptoms.
Over time, the field has shifted toward more precise interventions aimed directly at the root cause of the illness, including drugs that interfere with IGF-1R. In 2020, teprotumumab became the first FDA-approved biologic for TED, followed by veligrotug in June 2026, which works irrespective of whether the disease is active or dormant.
Satralizumab would offer a mechanistically distinct approach by inhibiting IL-6 signaling. IL-6 is an inflammatory cytokine involved in immune activation, and increased IL-6 signaling has been implicated in orbital inflammation and tissue changes associated with TED.
However, the SatraGO studies weren’t designed to pit satralizumab head-to-head against either of the currently available IGF-1R-targeting medications, leaving questions about how well it stacks up in terms of effectiveness and safety. Administration method might also set it apart from other treatments now on the market.
Related Post: New Alzheimer’s drug safety under scrutiny
Teprotumumab requires 8 intravenous infusions administered every 3 weeks, whereas veligrotug requires 5 infusions at the same interval. In contrast, satralizumab was administered subcutaneously every 4 weeks following an initial loading period in phase 3 trials.
Treatment Options Expanding
As the FDA considers Genentech’s application, it is clear that satralizumab has the potential to expand treatment choices for patients with TED, particularly those for whom IGF-1R–directed treatment is unsuitable. However, the divergent primary-endpoint results across the two key trials remain important when interpreting the evidence.
The SatraGO clinical trial program included two identically designed, 72-week, double-masked, placebo-controlled phase 3 trials that enrolled a combined 258 adults with active, moderate-to-severe TED or chronic inactive TED. Participants were randomized 1:1 to satralizumab or placebo.
The primary efficacy endpoint was the proportion of patients with active TED who achieved a proptosis response at week 24, defined as a reduction of at least 2 mm from baseline in the study eye without a corresponding worsening of at least 2 mm in the fellow eye. SatraGO-2 met its primary endpoint: 52.9% of satralizumab-treated patients achieved a proptosis response versus 23.4% with placebo.
In SatraGO-1, response rates were 49.0% versus 31.2%, respectively; the difference did not reach statistical significance. Investigators noted that the placebo response was higher in SatraGO-1 than in SatraGO-2, reducing the observed treatment difference.
Secondary measures of inflammatory disease activity also favored satralizumab. A reduction of at least 2 points in Clinical Activity Score (CAS) occurred in 78% of patients receiving satralizumab versus 54.9% taking placebo in SatraGO-1, and 89.6% versus 63.3% in SatraGO-2.
Among patients with diplopia at baseline, an improvement of at least 1 grade occurred in 44.4% of satralizumab-treated patients versus 34.4% with placebo in SatraGO-1 and 60.7% versus 25.8% in SatraGO-2. The trials did not include active comparators, and restrictions on prior TED therapies may limit the generalizability of the findings to previously treated patients.
Safety Profile Under Review
As the FDA weighs the evidence, satralizumab’s safety profile will be examined. In the SatraGO trials, adverse events were reported. No serious infections occurred in the satralizumab arms, and no fatal adverse events were reported. Nasopharyngitis and headache were among the adverse events reported during the TED trials.
Pretreatment screening for hepatitis B virus and tuberculosis is required, as well as assessment of liver transaminases and bilirubin, with ongoing laboratory monitoring during treatment. The label also advises against live or live-attenuated vaccines during treatment. The most common adverse effects seen in NMOSD clinical trials include nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea.